A lawsuit filed in federal court on behalf of the University of Pennsylvania and its health system alleges that 20 years of skyrocketing prices on drugs that treat diabetes, like insulin, can be blamed on price-fixing by the top U.S. drugmakers and Pharmacy Benefit Managers. The pharmaceutical companies named as defendants in the lawsuit, filed July 11, are Eli Lilly, Novo Nordisk and Sanofi. They are accused in court papers of colluding with pharmacy benefit managers, or PBMs, including CVS Caremark, Express Scripts and OptumRX, to inflate prices over the years.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
